Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeMedovateSAFIRA® Anaesthesia Device Receives European CE Regulatory Approval

SAFIRA® Anaesthesia Device Receives European CE Regulatory Approval

September 17, 2020

SAFIRA ® (SAFer Injection for Regional Anaesthesia) has received CE Mark Approval. The news was announced today by Medovate.

SAFIRA ® is a revolutionary new technology that transforms regional anesthesia into a one-person procedure, putting control in the hands of the anesthetist.

The Class II medical device provides a unique safety solution that monitors and limits injection pressure, helping to improve patient safety by reducing the risk of nerve damage following injection. In addition, economic modeling shows it has the potential to generate significant time and cost savings.

Developed in collaboration with anesthetists in the UK National Health Service (NHS), the device was successfully launched in the US earlier this year, having secured FDA clearance, bringing Medovate’s first medtech innovation to market.

Successful CE certification marks a key milestone for the fast-growing company, itself established just over two years ago. As a UK-based enterprise, this regulatory approval is essential as it continues to expand in territories across the world.

Alan Finnerty, Technology Director, Medovate commented: “We are thrilled to announce CE mark approval for our pioneering technology. Given the significant benefits SAFIRA® brings to both clinicians and patients, we are confident that our ability to enter the European market will help deliver improved outcomes for patients undergoing regional anesthesia procedures, as well as generate unique cost optimization benefits for healthcare.”

Stuart Thomson, Managing Director, Medovate commented “SAFIRA® CE certification is an important leap forward for our company as we continue to expand our footprint and presence globally. The entire Medovate team has worked extremely hard to deliver both US FDA clearance and EU CE approval for this technology within the last six months.

Our goal is to provide clinicians with an innovative solution to carry out regional anesthesia procedures effectively at safer pressures. This is especially important in the current healthcare climate which is facing many challenges.”

The European and American Societies of Regional Anaesthesia have recently produced joint COVID-19 recommendations stating that regional anesthesia should be preferred over general anesthesia whenever surgery is planned for suspected or confirmed COVID-19 patients.

This is because regional anesthesia, which involves numbing only the area of the body that requires surgery, preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19 compared to general anesthesia. In enabling regional anesthesia to be carried out as a one-person procedure, Medovate’s innovative technology, SAFIRA®, further compliments these recent recommendations.

Now, with both CE Mark Approval and FDA Clearance, SAFIRA® can be readily integrated into healthcare markets across Europe and the US.

Other news.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy